Van Buren DH - Search Results

1

Long-term efficacy and safety of cyclosporine in renal-transplant recipients.

Burke JF Jr, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC. Burke JF Jr, et al. Among authors: van buren dh. N Engl J Med. 1994 Aug 11;331(6):358-63. doi: 10.1056/NEJM199408113310604. N Engl J Med. 1994. PMID: 8028616 Free article.

2

Chronic immunosuppression of the renal transplant patient.

Helderman JH, Van Buren DH, Amend WJ Jr, Pirsch JD. Helderman JH, et al. Among authors: van buren dh. J Am Soc Nephrol. 1994 Feb;4(8 Suppl):S2-9. doi: 10.1681/ASN.V48s2. J Am Soc Nephrol. 1994. PMID: 8193291 Review.

3

Renal function in patients receiving long-term cyclosporine therapy.

Van Buren DH, Burke JF, Lewis RM. Van Buren DH, et al. J Am Soc Nephrol. 1994 Feb;4(8 Suppl):S17-22. doi: 10.1681/ASN.V48s17. J Am Soc Nephrol. 1994. PMID: 8193290 Review.

4

Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients.

Curtis JJ, Barbeito R, Pirsch J, Lewis RM, Van Buren DH, Choudhury S. Curtis JJ, et al. Among authors: van buren dh. Am J Kidney Dis. 1999 Nov;34(5):869-74. doi: 10.1016/S0272-6386(99)70044-2. Am J Kidney Dis. 1999. PMID: 10561143 Clinical Trial.

5

The effect of polyimmune gammaglobulin for prophylaxis against reactivation cytomegalovirus infection in kidney and kidney/pancreas transplant recipients.

McCune TR, Johnson HK, MacDonell RC Jr, Richie RE, Nylander WA, Van Buren DH, Helderman JH. McCune TR, et al. Among authors: van buren dh. J Am Soc Nephrol. 1992 Apr;2(10):1469-74. doi: 10.1681/ASN.V2101469. J Am Soc Nephrol. 1992. PMID: 1376177 Clinical Trial.

6

Experience with neoral versus sandimmune in primary liver transplant recipients.

Pinson CW, Chapman WC, Wright JK, Hunter EB, Awad JA, Raiford DS, Payne JL, Geevarghese S, Blair TK, Van Buren DH. Pinson CW, et al. Among authors: van buren dh. Transpl Int. 1998;11 Suppl 1:S278-83. doi: 10.1007/s001470050479. Transpl Int. 1998. PMID: 9664997 Clinical Trial.

7

Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).

Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW. Van Buren D, et al. Transplant Proc. 1998 Jun;30(4):1401-2. doi: 10.1016/s0041-1345(98)00289-9. Transplant Proc. 1998. PMID: 9636566 Clinical Trial.

8

Colonic screening prior to renal transplantation and its impact on post-transplant colonic complications.

McCune TR, Nylander WA, Van Buren DH, Richie RE, MacDonell RC Jr, Johnson HK, Shull H Jr, Cate CK, Helderman JH. McCune TR, et al. Among authors: van buren dh. Clin Transplant. 1992 Apr;6(2):91-6. Clin Transplant. 1992. PMID: 10150089

9

De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine.

Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD. Van Buren D, et al. Surgery. 1985 Jul;98(1):54-62. Surgery. 1985. PMID: 3892747

10

Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.

Van Buren D, Payne J, Geevarghese S, MacDonell R, Chapman W, Wright JK, Helderman JH, Richie R, Pinson CW. Van Buren D, et al. Transplant Proc. 1998 Aug;30(5):1830-2. doi: 10.1016/s0041-1345(98)00448-5. Transplant Proc. 1998. PMID: 9723299 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters